vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ZK International Group Co., Ltd. (ZKIN). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $108.2M, roughly 1.8× ZK International Group Co., Ltd.).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ZK International Group Co., Ltd. is a China-based enterprise focused on the research, development, design, manufacturing and sale of high-quality stainless steel piping systems and fluid transport supporting products. Its offerings cater to construction, municipal infrastructure and residential engineering segments, with core markets spanning China and selected overseas regions.
AXSM vs ZKIN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $108.2M |
| Net Profit | — | $-2.8M |
| Gross Margin | — | 6.1% |
| Operating Margin | -33.1% | -1.6% |
| Net Margin | — | -2.6% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | — | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | $108.2M | ||
| Q2 24 | $87.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | — | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-2.8M | ||
| Q2 24 | $-79.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | — |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | -1.6% | ||
| Q2 24 | -89.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -2.6% | ||
| Q2 24 | -91.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | $-0.57 | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $4.1M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $28.2M |
| Total Assets | $713.6M | $80.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | $4.1M | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | — | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | $28.2M | ||
| Q2 24 | $102.9M | — |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | — | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | $80.0M | ||
| Q2 24 | $548.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-6.9M |
| Free Cash FlowOCF − Capex | — | $-7.5M |
| FCF MarginFCF / Revenue | — | -6.9% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | $-6.9M | ||
| Q2 24 | $-30.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | $-7.5M | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | -6.9% | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
ZKIN
Segment breakdown not available.
